Helix Biopharma Corp. HBPCF
—
1.71
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow HBPCF
Growth Flags
show if company had growth for consecutive years
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Older periods | |
|---|---|---|---|---|---|
| (49.65%) | (54.46%) | (65.79%) | (67.19%) |
+8 more TTM periods Free account |
|
| (29.64%) | (40.34%) | (49.56%) | (51.21%) | ||
ROIC |
(16.60%) | (16.32%) | (18.32%) | (21.21%) | |
Return on Tangible Assets |
89.55% | 137.97% | 207.87% | 185.69% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.04) | (0.04) | (0.05) | |
Free Cash Flow |
(2.37) | (2.69) | (3.00) | (2.73) | |
Capital Expenditures |
— | — | — | 0.01 | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(18.19%) | (23.68%) | (24.58%) | (23.96%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.89 | 0.86 | 0.74 | |
Depreciation/Fixed assets |
4.43 | 7.43 | 4.07 | 2.48 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 1.69 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.03) | (0.04) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates